OR6C4

Across TCGA pan-cancer cohorts, OR6C4 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated OR6C4 data layer compared with 3 for mutation status.

The strongest signal is observed in sarcoma (SARC), where higher OR6C4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR6C4 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCS show a favorable association.

SARC, PAAD, and UCEC are the cancer types where OR6C4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Tertile	All	0.265	0.749	<.001	45	view →
PAAD	OS	Tertile	II,III,IV	0.146	0.557	<.001	36	view →
UCEC	OS	Tertile	All	0.490	0.687	.003	30	view →
KIRC	OS	Tertile	All	0.688	0.808	.024	27	view →
THCA	DFS	Tertile	All	0.116	0.916	<.001	27	view →
SKCM	DFS	Tertile	II,III,IV	0.904	0.678	.017	15	view →
UCS	DFS	Tertile	III,IV	1.000	0.222	.046	12	view →
LGG	DFS	Tertile	All	0.287	0.759	.004	9	view →
STAD	DFS	Tertile	III,IV	0.887	0.554	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

OR6C4–SARC (OS)

Open the SARC breakdown →